Merck and Bayer Report Results of Vericiguat in P-III VICTORIA Study for Patients with Worsening Chronic Heart Failure

 Merck and Bayer Report Results of Vericiguat in P-III VICTORIA Study for Patients with Worsening Chronic Heart Failure

Merck’s Keytruda (pembrolizumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma (HCC)

Shots:

  • The P-III VICTORIA study involves assessing of Vericiguat vs PBO in combination with available HF therapies in 5,050 patients with worsening chronic heart failure with reduced ejection fraction (HFrEF) following a decompensation event across 600 centers in 42 countries
  • The P-III VICTORIA study resulted in meeting its 1EPs i.e, reduction in heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure with HFrEF
  • Vericiguat is an investigational soluble guanylate cyclase (sGC) stimulator, jointly developed by Merck and Bayer. In Oct’2014, Bayer and Merck entered into a WW collaboration to develop sGC modulators

Click here to­ read full press release/ article | Ref: Merck | Image: Brands Vietnam

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post